Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study

被引：4

作者：

Xu, R-H. ^{[1
]}

Oh, D-Y. ^{[2
]}

Kato, K. ^{[3
]}

Arkenau, T. ^{[4
]}

Tabernero, J. ^{[5
]}

Cruz-Correa, M. ^{[6
]}

Zimina, A. ^{[7
]}

Bai, Y. ^{[8
]}

Shi, J. ^{[9
]}

Lee, K-W. ^{[10
]}

Hirano, H.

Spigel, D. R. ^{[11
]}

Wyrwicz, L. S. ^{[12
]}

Cid, R. A. Pazo ^{[13
]}

Li, L. ^{[14
]}

Xu, Y. ^{[15
]}

McHenry, M. B. ^{[16
]}

Yang, S. ^{[14
]}

Moehler, M. ^{[17
]}

机构：

[1] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, Canc Ctr,State Key Lab Oncol South China, Guangzhou, Peoples R China

[2] Seoul Natl Univ, Hosp Canc Res Inst, Dept Internal Med, Coll Med, Seoul, South Korea

[3] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan

[4] Sarah Cannon Res Inst, Dept Drug Dev, London, England

[5] Vall dHebron Hosp Campus & Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain

[6] Univ Puerto Rico, Sch Med, San Juan, PR USA

[7] BIH Omsk Region, Dept Oncol, Clin Oncol Dispensary, Omsk, Russia

[8] Harbin Med Univ, Dept Gastrointestinal Oncol, Canc Hosp, Harbin, Peoples R China

[9] Linyi Canc Hosp, Dept Med Oncol 2, Linyi, Shandong, Peoples R China

[10] Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seongnam, Gyeonggi Do, South Korea

[11] Tennessee Oncol, Dept Thorac Med Oncol, Nashville, TN USA

[12] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Oncol & Radiotherapy, Warsaw, Poland

[13] Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain

[14] BeiGene Beijing Co Ltd, Clin Dev Clin Biomarker, Beijing, Peoples R China

[15] BeiGene Shanghai Co Ltd, Clin Dev, Shanghai, Peoples R China

[16] BeiGene USA Inc, GSDS, Cambridge, MA USA

[17] Johannes Gutenberg Univ Clin, Dept Internal Med 1, Mainz, Germany

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.081

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA80

引用

页码：S1320 / S1321

页数：2

共 50 条

[41] RATIONALE-304 long-term outcomes: First-line tislelizumab (TIS) plus chemotherapy (chemo) vs chemo for locally advanced or metastatic non-squamous (NSQ) NSCLC
Ma, Z.
Yu, Y.
Yu, X.
Li, X.
Cui, J.
Wang, D.
Wang, X.
Wu, J.
Huang, D.
Li, G.
Zhao, N.
Liang, L.
Song, M.
Lu, S.
ANNALS OF ONCOLOGY, 2024, 35 : S1637 - S1637
[42] RATIONALE 307: Tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) in patients (pts) who were smokers vs non-smokers
Yu, X.
Wang, J.
Lu, S.
Zhao, J.
Yu, Y.
Hu, C.
Feng, G.
Ying, K.
Zhuang, W.
Zhou, J.
Wu, J.
Leaw, S. J.
Lin, X.
Zhang, J.
ANNALS OF ONCOLOGY, 2021, 32 : S1005 - S1005
[43] Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
Qiu, Hai-Bo
THORACIC CANCER, 2020, 11 (12) : 3419 - 3421
[44] First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up.
Kojima, Takashi
Ogata, Takashi
Ishihara, Ryu
Hara, Hiroki
Sun, Tianmo
Xu, Sheng
Kato, Ken
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 420 - 420
[45] Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective
Li, Wei
Wan, Li
Zhang, Jiangyan
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 18 (06) : 293 - 301
[46] Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
Xu, J.
Jiang, H.
Pan, Y.
Gu, K.
Cang, S.
Han, L.
Shu, Y.
Li, J.
Zhao, J.
Pan, H.
Luo, S.
Qin, Y.
Guo, Q.
Bai, Y.
Ling, Y.
Guo, Y.
Li, Z.
Liu, Y.
Wang, Y.
Zhou, H.
ANNALS OF ONCOLOGY, 2021, 32 : S1331 - S1331
[47] RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC
Wang, J.
Lu, S.
Wang, Z.
Hu, C.
Sun, Y.
Yang, K.
Chen, M.
Zhao, J.
Liang, L.
Huo, Y.
Zhang, Y.
Huang, R.
Wu, X.
Ma, X.
Leaw, S. J.
Bai, F.
Shen, Z.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S950 - S951
[48] Neoadjuvant/adjuvant pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585
Shitara, Kohei
Bang, Yung-Jue
Wyrwicz, Lucjan S.
Rha, Sun Young
Oshima, Takashi
Di Bartolomeo, Maria
Park, Young-Kyu
Lonardi, Sara
Weber, Patricio Eduardo Yanez
Yen, Chia-Jui
Metges, Jean-Philippe
Garrido, Marcelo
Moehler, Markus H.
Pelles-Avraham, Sharon
Yong, Wei-Peng
Spallanzani, Andrea
Jensen, Erin
Krishnan, Radha
Shih, Chie-Schin
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[49] Phase (Ph) II study of zanidatamab plus chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)
Ku, G.
Elimova, E.
Denlinger, C. S.
Mehta, R.
Lee, K-W.
Iqbal, S.
Kang, Y-K.
Oh, D-Y.
Rha, S. Y.
Kim, Y. H.
Seol, Y. M.
Mwatha, T.
Grim, J.
Ajani, J. A.
ANNALS OF ONCOLOGY, 2021, 32 : S1044 - S1045
[50] First-line lenvatinib (Len) plus pembrolizumab (Pembro) plus chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in
Shitara, K.
Ben-Aharon, I.
Rojas, C.
Eyzaguirre, D. A. Acosta
Hubert, A.
Moya, H. Araya
Cohen, D.
Bai, L-Y.
Ghiringhelli, F.
Wyrwicz, L.
Janjigian, Y. Y.
Tabernero, J.
Van Cutsem, E.
Qin, S.
Xu, J.
Wang, A.
Miller, M. G.
Shih, C-S.
Bhagia, P.
Weber, P. E. Yanez
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1108 - S1108

← 1 2 3 4 5 →